Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CUL4A | Q13619 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 6/20 | 0.34 |
| ▸ | AKR1C1 | Q04828 | 6/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KLK7 | P49862 | 1/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.32 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.30 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.30 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.30 |
| ▸ | GMNN | O75496 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6292345 | 0.91 | CUL4A (0.47) | CUL4AAKR1C3AKR1C1MAPTKLK7 | |
| SCHEMBL6297468 | 0.89 | CUL4A (0.38) | CUL4AAKR1C3AKR1C1MAPTKLK7 | |
| SCHEMBL6760910 | 0.84 | NR3C2 (0.33) | MAPTNR3C2KDM4EALDH1A1TP53 | |
| SCHEMBL7438969 | 0.84 | CACNA1C (0.36) | MAPTCACNA1CKMT2AKDM4EALDH1A1 | |
| SCHEMBL7435633 | 0.84 | CACNA1C (0.36) | MAPTCACNA1CKMT2AKDM4EALDH1A1 | |
| SCHEMBL6293389 | 0.84 | NR3C2 (0.34) | CUL4AAKR1C3AKR1C1MAPTNR3C2 | |
| SCHEMBL6760937 | 0.83 | CACNA1C (0.35) | MAPTCACNA1CKMT2AKDM4EALDH1A1 | |
| SCHEMBL6292198 | 0.82 | CUL4A (0.49) | CUL4AMAPTKLK7CACNA1CKMT2A | |
| SCHEMBL6293363 | 0.82 | CACNA1C (0.46) | MAPTCACNA1CNR3C2KMT2AKDM4E | |
| SCHEMBL6297275 | 0.81 | CDK1 (0.40) | MAPTNR3C2KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6977262-B2 | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2005-12-20 | — | — | US | claimed |
| US-20040052822-A1 | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-03-18 | — | — | US | claimed |
| US-6977262-B2 | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2005-12-20 | — | — | US | disclosed |
| US-20040052822-A1 | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1355909-A2 | DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002062795-A2 | DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | MITSUBISHI PHARMA CORPORATION (JP) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040052822-A1 | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | GSK3B, GSK3A, PYGB | CUL4A 3202/4885AKR1C3 1646/4885AKR1C1 1357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.